InsidersTradesSigma
Follow the 华海药业 share price and the full management transaction log of the company, a publicly traded company based in China. Shares are quoted on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 华海药业 has published 3 public disclosures. Market capitalisation: €24.4bn. The latest transaction was reported on 27 November 2023 (Purchase). Among the most active insiders: 陈保华. All data is free.
3
Insider Decl.
n/a
Thresholds
€3m
3 ops.
Buy Volume
n/a
n/a
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,591 of 28,932 companies
37.5
score / 100
Value31
Quality44
FCF yld-3.0%
Earn yld1.1%
EV/EBITDA19.2x
ROE3.3%
Gross mgn60%
Net mgn3.1%
Debt/EBITDA4.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 27 November 2023
About 华海药业
华海药业 is a company in the health and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the research, development, and production of generic drugs and innovative pharmaceutical products.